HomepageAUROPHARMA • NSE
add
Aurobindo Pharma
Vorige slotkoers
₹ 1.167,70
Dag-range
₹ 1.158,00 - ₹ 1.189,10
Jaar-range
₹ 1.010,00 - ₹ 1.278,60
Beurswaarde
685,35 mld. INR
Gem. volume
778,40K
Koers/winst
20,02
Dividendrendement
0,34%
Primaire beurs
NSE
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (INR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 82,86 mld. | 6,28% |
Bedrijfskosten | 36,98 mld. | 8,70% |
Netto inkomsten | 8,48 mld. | 3,80% |
Netto winstmarge | 10,24 | -2,29% |
Winst per aandeel | 14,61 | 4,36% |
EBITDA | 16,66 mld. | 5,66% |
Effectief belastingtarief | 33,53% | — |
Balans
Totale activa
Totale passiva
| (INR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 88,92 mld. | 29,47% |
Totale activa | 525,46 mld. | 9,26% |
Totale passiva | 175,12 mld. | 1,76% |
Totaal aandelenvermogen | 350,34 mld. | — |
Uitstaande aandelen | 580,73 mln. | — |
Koers-boekwaardeverhouding | 1,94 | — |
Rendement op activa | — | — |
Rendement op kapitaal | 7,46% | — |
Kasstroom
Nettomutatie in liquide middelen
| (INR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 8,48 mld. | 3,80% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
Opgericht
1986
Hoofdvestiging
Website
Werknemers
27.707
